Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 5;9(9):CD006682.
doi: 10.1002/14651858.CD006682.pub6.

Duration of intravenous antibiotic therapy in people with cystic fibrosis

Linsey Abbott  1 , Amanda Plummer, Zhe Hui Hoo, Martin Wildman
Affiliations

Duration of intravenous antibiotic therapy in people with cystic fibrosis

Linsey Abbott et al. Cochrane Database Syst Rev. .

Abstract

Background: Progressive lung damage from recurrent exacerbations is the major cause of mortality and morbidity in cystic fibrosis. Life expectancy of people with cystic fibrosis has increased dramatically in the last 40 years. One of the major reasons for this increase is the mounting use of antibiotics to treat chest exacerbations caused by bacterial infections. The optimal duration of intravenous antibiotic therapy is not clearly defined. Individuals usually receive intravenous antibiotics for 14 days, but treatment may range from 10 to 21 days. A shorter duration of antibiotic treatment risks inadequate clearance of infection which could lead to further lung damage. Prolonged courses of intravenous antibiotics are expensive and inconvenient. The risk of systemic side effects such as allergic reactions to antibiotics also increases with prolonged courses and the use of aminoglycosides requires frequent monitoring to minimise some of their side effects. However, some organisms which infect people with cystic fibrosis are known to be multi-resistant to antibiotics, and may require a longer course of treatment. This is an update of previously published reviews.

Objectives: To assess the optimal duration of intravenous antibiotic therapy for treating chest exacerbations in people with cystic fibrosis.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals, abstract books and conference proceedings. Most recent search of the Group's Cystic Fibrosis Trials Register: 30 May 2019.We also searched online trials registries. Most recent search of the ClinicalTrials.gov and WHO International Clinical Trials Registry Platform (ICTRP) portal: 06 January 2019.

Selection criteria: Randomised and quasi-randomised controlled trials comparing different durations of intravenous antibiotic courses for acute respiratory exacerbations in people with CF, either with the same drugs at the same dosage, the same drugs at a different dosage or frequency or different antibiotics altogether, including studies with additional therapeutic agents.

Data collection and analysis: No eligible trials were identified for inclusion. A trial looking at the standardised treatment of pulmonary exacerbations is currently ongoing and will be included when the results are published. MAIN RESULTS: No eligible trials were included.

Authors' conclusions: There are no clear guidelines on the optimum duration of intravenous antibiotic treatment. Duration of treatment is currently based on unit policies and response to treatment. Shorter duration of treatment should improve quality of life and adherence, result in a reduced incidence of drug reactions and be less costly. However, the shorter duration may not be sufficient to clear a chest infection and may result in an early recurrence of an exacerbation. This systematic review identifies the need for a multicentre, randomised controlled trial comparing different durations of intravenous antibiotic treatment as it has important clinical and financial implications. The currently ongoing STOP2 trial is expected to provide some guidance on these questions when published.

PubMed Disclaimer

Conflict of interest statement

Martin Wildman works intensively in the area of adherence working to understand how preventative nebulised treatment can decrease the need for IV antibiotics. He has received support from Respironics in terms of salary support for a research fellow who has worked on adherence research. He has also received funding from Smiths Medical for work around adherence device developments, funding from Pari to develop software to measure drug duration, and funding from Philips to use airflow data to try to predict exacerbations. He has also been paid for consultancy relating to adherence by Vertex Inc (Vertex do not manufacture or market antibiotics).

Amanda Plummer has received an honrarium from Profile Pharmaceuticals and from the Chiesi advisory board related to preventative nebulised treatment; these do not constitute a conflict of interest for this review which is looking at the duration of intravenous antibiotic treatment.

Linsey Abbott declares no known potential conflict of interest.

Zhe Hui Hoo declares funding from a CF Trust clinical fellowship (Award Identifier CF007).

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Adeboyeku 2011 {published data only}
    1. Adeboyeku D, Jones AL, Hodson ME. Twice vs three‐times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):25‐30. [CFGD Register: PI250] - PubMed
Blumer 2005 {published data only}
    1. Blumer JL, Minkwitz M, Saiman L, San Gabriel P, Iaconis J, Melnick D. Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or burkholderia cepacia (BC) [abstract]. Pediatric Pulmonology 2003;Suppl 25:294. [CFGD Register: PI179a]
    1. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128(4):2336‐46. [CFGD Register: PI179b] - PubMed
Hjelte 1988 {published data only}
    1. Hjelte L, Widen B, Malmborg AS, Freyschuss U, Strandvik B. Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life [Intravenos antibiotikabehandling i hemmet vid cystisk fibros ger okad livskvalitet]. Lakartidningen 1988;85(18):1614‐7. [CFGD Register: PI206] - PubMed
Hubert 2009 {published data only}
    1. Hubert D, Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrobial Agents and Chemotherapy 2009;53(9):3650‐6. [CFGD Register: PI180b] - PMC - PubMed
    1. Hubert D, Wallaert B, Scheid P, Ramel S, Grenet D, Sermet‐Gaudelus I, et al. Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2003;Suppl 25:294. [CFGD Register: PI180a]
    1. NCT00333385. Continuous versus short infusions of ceftazidime in cystic fibrosis. https://clinicaltrials.gov/show/NCT00333385 2006. [CFGD Register: PI180c]
Kapranov 1995 {published data only}
    1. Kapranov NI, Belousov YB, Kashyrskaya NY, Smirnova EY. Quinoline therapy in children with cystic fibrosis [abstract]. Proceedings of 20th European Cystic Fibrosis Conference; 1995 June 18‐21; Brussels, Belgium. 1995:P19. [CFGD Register: PI104]
Keel 2011 {published data only}
    1. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393‐8. [CFGD Register: PI251] - PMC - PubMed
Kenny 2009 {published data only}
    1. Kenny S, Hall V, Goldsmith C, Moore J, Rendall JC, Elborn JS. Eradication of Pseudomonas aeruginosa in adults with CF [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S39, Abstract no: 158. [CFGD Register: PI229]
Knight 1979 {published data only}
    1. Knight RK, Batten JC, Mearns M. A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum [abstract]. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12‐13; Noordwijkerhout, The Netherlands. 1979:52. [CFGD Register: PI124]
Latzin 2008 {published data only}
    1. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis 2008;7(2):142‐6. [CFGD Register: PI209; MEDLINE: ] - PubMed
NCT01044719 {published data only}
    1. EUCTR 2009‐014042‐28‐GB. What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? ‐ Duration of antibiotics in infective exacerbations of cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐014042‐28‐GB (first received 14 October 2010). [CFGD Register: PI314b]
    1. NCT01044719. Duration of antibiotics in infective exacerbations of cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01044719 (first received 08 January 2010). [CFGD Register: PI314a]
Postnikov 2007 {published data only}
    1. Postnikov SS, Semykin SY, Polikarpova SV, Dubovik LG, Gracheva LA, Sagatelyan RM. A prospective trial on the efficacy and tolerability of twice‐daily dosing (TDD) versus once‐daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2007;6(Suppl 1):S34. [CFGD Register: PI204]
Riethmueller 2009 {published data only}
    1. Riethmueller J, Ballmann M, Schroeter TW, Franke P, Butler R, Claass A, et al. Tobramycin once‐ vs thrice‐daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37(5):424‐31. [CFGD Register: PI154f] - PubMed
    1. Riethmueller J, Busch A, Franke P, Ziebach R, Butler R, Stern M. Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF‐patients is equally effective [abstract]. Proceedings of 13th international cystic fibrosis congress; 2000 June 4‐8; Stockholm, Sweden. 2000:166. [CFGD Register: PI154a]
    1. Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al. Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract]. Proceedings of 24th European cystic fibrosis conference; 2001 June 6‐9; Vienna, Austria. 2001:P192. [CFGD Register: PI154b]
    1. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al. Continuous vs thrice‐daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37(5):418‐23. [CFGD Register: PI154e] - PubMed
    1. Schroeter T, Eggert P, Riethmueller J, Stern M, Claass A. Acute‐phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once‐versus thrice‐daily dosing [abstract]. Pediatric Pulmonology 2002;Suppl 24:289. [CFGD Register: PI154d]
Semykin 2010 {published data only}
    1. Semykin SY, Polikarpova SV, Dubovik LG, Kashirskaya NY. Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2010;9 Supplement 1:S55, Abstract no: 214. [CFGD Register: PI246]
STOP 2017 {published data only}
    1. West NE, Beckett VV, Jain R, et Al. Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations.. J Cyst Fibros 2017;16(5):600‐606. - PMC - PubMed

References to ongoing studies

STOP2 {published data only}
    1. Flume PA, Heltshe SL, West NE, Vandevanter DR, Sanders DB, Skalland M, et al. Design, enrolment, and feasibility of the STOP‐2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis 2018;17 Suppl 3:S85. [CFGD Register: PI298a]
    1. Heltshe S, West NE, VanDevanter DR, Sanders DB, Skalland M, Beckett V, et al. Design, enrollment, and feasibility of the STOP‐2 randomised study of iv antibiotic duration in CF pulmonary exacerbations. Pediatric Pulmonology 2017;52(Suppl 47):388. [CFGD Register: PI298b]
    1. Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, et al. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials 2018;64:35‐40. [CFGD Register: PI298c] - PMC - PubMed
    1. NCT02781610. Standardized treatment of pulmonary exacerbations II (STOP2). clinicaltrials.gov/ct2/show/NCT02781610 (first posted 24 May 2016).
    1. Sanders DB, Heltshe S, West NE, VanDevanter DR, Skalland M, Flume P, et al. Update on the STOP‐2 randomized study of IV antibiotic duration in CF pulmonary exacerbations. Pediatric Pulmonology 2018;53(S2):324. [CFGD Register: PI298d]

Additional references

Balaguer 2008
    1. Balaguer A, González de Dios J. Home intravenous antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD001917.pub2] - DOI - PubMed
BTS 2017
    1. British Thoracic Society. British Thoracic Society guidelines for the management of non‐tuberculosis mycobacterial pulmonary disease (NTM‐PD). Thorax November 2017; Vol. 72, issue 2. - PubMed
CF Foundation 1994
    1. Cystic Fibrosis Foundation. Microbiology and Infectious disease in cystic fibrosis. Consensus Conference, Bethesda 1994; Vol. V (Section 1):1‐26.
CF Foundation 2001
    1. Cystic Fibrosis Foundation. National Patient Registry. Annual Data Report 2000 [Bethesda, Maryland] 2001.
CF Trust 2009
    1. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Group. 3rd 2009.
Cheng 1996
    1. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta‐lactam‐resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9041):1596‐7. - PubMed
Demko 1995
    1. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. Journal of Clinical Epidemiology 1995;48(8):1041‐9. - PubMed
Donaldson 2003
    1. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. Current Opinion in Pulmonary Medicine 2003;9(6):486‐91. - PubMed
Doring 2000
    1. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal 2000;16(4):749‐67. - PubMed
Döring 2012
    1. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Journal of Cystic Fibrosis 2012;11(6):461‐79. - PubMed
Edenborough 2004
    1. Edenborough FP, Stone HR, Kelly SJ, Zadik P, Doherty CJ, Govan JR. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. Journal of Cystic Fibrosis 2004;3(1):37‐44. - PubMed
Elborn 2004
    1. Elborn JS. Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis. Thorax 2004;59(11):914‐5. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Emerson 2002
    1. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology 2002;34(2):91‐100. - PubMed
Farrell 2018
    1. Farrell P, Férec C, Macek M, Frischer T, Renner S, Riss K, et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics 2018;26(12):1832‐9. [DOI: 10.1038/s41431-018-0234-z] - DOI - PMC - PubMed
Flume 2009
    1. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180(9):802‐8. - PubMed
Frangolias 1999
    1. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittmann R, et al. Burkholderia cepacia in cystic fibrosis: variable disease course. American Journal of Respiratory and Critical Care Medicine 1999;160(5 Pt 1):1572‐7. - PubMed
Gibson 2003
    1. Gibson RL, Burns JL, Ramsey RL. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918‐51. - PubMed
Gilligan 1999
    1. Gilligan PH. Microbiology of CF Lung Disease. In: Yankaskas JR, Knowles MR editor(s). Cystic Fibrosis in Adults. Philedelpia: Lippincott‐Raven, 1999:93‐114.
Hansen 2008
    1. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas Aeruginosa airway colonisation in cystic fibrosis patients: 15 years experience. Journal of Cystic Fibrosis 2008;7(6):523‐30. - PubMed
Hentzer 2001
    1. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. Journal of Bacteriology 2001;183(18):5395‐401. - PMC - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org.
Hodson 2000
    1. Hodson ME. Treatment of cystic fibrosis in the adult. Respiration 2000;67(6):595‐607. - PubMed
Horre 2004
    1. Horre R, Schaal KP, Siekmeier R, Sterzik B, Hoog GS, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 2004;71(4):360‐6. - PubMed
Høiby 2000
    1. Høiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatric Drugs 2000;2(6):451‐63. - PubMed
Jones 2001
    1. Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358(9281):557‐8. - PubMed
Jones 2002
    1. Jones AM, Dodd ME, Doherty CJ, Govan JR, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57(11):924‐5. - PMC - PubMed
Keogh 2018
    1. Keogh, R. Up‐to‐date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data. Journal of Cystic Fibrosis 2018;17(2):218‐27. - PMC - PubMed
Koch 1991
    1. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al. Retrospective clinical study of hypersensitivity reactions to astreonam and six other beta‐lactam antibiotics in cystic fibrosis patients receiving multiple antibiotic courses. Reviews of Infectious Diseases 1991;13(Suppl 7):S608‐11. - PubMed
Lechtzin 2006
    1. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic‐resistant Pseudomonas aeruginosa. Respiration 2006;73(1):27‐33. - PubMed
Olesen 2006
    1. Olesen HV, Nielsen LP, Schiotz PO. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatric Pulmonology 2006;41(12):1197‐204. - PubMed
Parkins 2012
    1. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012;141(2):484‐93. - PubMed
Parmar 2005
    1. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax 2005;60(6):517‐20. - PMC - PubMed
Penketh 1987
    1. Penketh AR, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic fibrosis in adolescents and adults. Thorax 1987;42(7):526‐32. - PMC - PubMed
Petersen 1981
    1. Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma ‐ possible synergism with Pseudomonas aeruginosa. Acta Paediatrica Scandinavica 1981;70(5):623‐8. - PubMed
Rabin 2004
    1. Rabin HR, Butler SM, Wohl MEB, Geller DE, Colin AA, Schidlow DV, et al. Pulmonary exacerbation in cystic fibrosis. Pediatric Pulmonology 2004;37(5):400‐6. - PubMed
Ramsey 1996
    1. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine 1996;335(3):179‐88. - PubMed
Schaedel 2002
    1. Schaedel C, Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatric Pulmonology 2002;33(6):483‐91. - PubMed
Starner 2005
    1. Starner TD, McCray PB Jr, American College of Physicians, American Physiological Society. Pathogenesis of early lung disease in cystic fibrosis: A window of opportunity to eradicate bacteria. Annals of Internal Medicine 2005;143(11):816‐22. - PubMed
Stephen 2018
    1. Stephen, MJ. Disadvantages of set length antibiotic treatment for pulmonary exacerbation. Lancet Respiratory Medicine 2018;6(8):573‐5. - PubMed
Stuart 2010
    1. Stuart B, Lin JH, Mogayzel Jr PJ. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Review article. Peadiatric Respiratory Reviews 2010;11(3):117‐84. - PMC - PubMed
UK CF Trust 2018
    1. UK Cystic Fibrosis Trust. Cystic Fibrosis strength in numbers UK Cystic Fibrosis Reigistry Annual Data Report 2017. www.cysticfibrosis.org.uk/˜/media/documents/the‐work‐we‐do/uk‐cf‐registr... 2018.
VanDevanter 2016
    1. VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.. J Cyst Fibros 2016;15(6):783‐790. - PMC - PubMed
Wat 2003
    1. Wat D. Impact of respiratory viral infections on cystic fibrosis. Postgraduate Medical Journal 2003;79(930):201‐3. - PMC - PubMed
Waters 2015
    1. Waters V, Stahojevic S, Klingel M, et Al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J. Cyst Fibros 2015;14(6):770‐776. - PubMed

References to other published versions of this review

Plummer 2011
    1. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006682.pub3] - DOI - PubMed
Plummer 2013
    1. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD006682.pub4] - DOI - PubMed
Plummer 2016
    1. Plummer A, Wildman M, Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD006682.pub5] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances